Parsabiv (Etelcalcetide Hydrochloride) Patent Expiration, LOE Window & CMS Spending
Parsabiv (Etelcalcetide Hydrochloride) by Amgen: FDA Orange Book core substance LOE 2031-02-07 (last listed 2034-06-27), 0 AB generics, $36.4M 2024 CMS Part D & Medicaid spend, and 12 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Amgen |
| FDA Application & Pathway | N208325 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2031-02-07 |
| Last Listed Patent or Exclusivity Date | 2034-06-27 |
| Orange Book Patents (*PED Extensions) | 8 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $36.4M |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $36.4M |
| Reported Wholesale Price Change (CA SB 17) | 12 WAC filings (max 16.8% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.